JP2019506838A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506838A5 JP2019506838A5 JP2018519334A JP2018519334A JP2019506838A5 JP 2019506838 A5 JP2019506838 A5 JP 2019506838A5 JP 2018519334 A JP2018519334 A JP 2018519334A JP 2018519334 A JP2018519334 A JP 2018519334A JP 2019506838 A5 JP2019506838 A5 JP 2019506838A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- cell
- cancer
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 56
- 210000004027 cell Anatomy 0.000 claims 20
- 206010028980 Neoplasm Diseases 0.000 claims 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims 15
- 238000000034 method Methods 0.000 claims 14
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 13
- 210000001519 tissue Anatomy 0.000 claims 13
- 239000013604 expression vector Substances 0.000 claims 11
- 108091008874 T cell receptors Proteins 0.000 claims 9
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 239000003446 ligand Substances 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 230000005847 immunogenicity Effects 0.000 claims 5
- 238000000338 in vitro Methods 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 238000010195 expression analysis Methods 0.000 claims 4
- 230000014509 gene expression Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 238000002659 cell therapy Methods 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108091023037 Aptamer Proteins 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 108091054437 MHC class I family Proteins 0.000 claims 2
- 102000043129 MHC class I family Human genes 0.000 claims 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000003139 biocide Substances 0.000 claims 2
- 230000022534 cell killing Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 108010028930 invariant chain Proteins 0.000 claims 2
- 239000012931 lyophilized formulation Substances 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 238000002493 microarray Methods 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 229920002477 rna polymer Polymers 0.000 claims 2
- 238000012163 sequencing technique Methods 0.000 claims 2
- 238000010186 staining Methods 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 238000011510 Elispot assay Methods 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims 1
- 210000003236 esophagogastric junction Anatomy 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000005934 immune activation Effects 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 229940038309 personalized vaccine Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000009257 reactivity Effects 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000003860 storage Methods 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 238000012070 whole genome sequencing analysis Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021063261A JP7513562B2 (ja) | 2015-12-11 | 2021-04-02 | 様々ながんに対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ |
| JP2023080911A JP2023113688A (ja) | 2015-12-11 | 2023-05-16 | 様々ながんに対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562266233P | 2015-12-11 | 2015-12-11 | |
| GBGB1521894.4A GB201521894D0 (en) | 2015-12-11 | 2015-12-11 | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| GB1521894.4 | 2015-12-11 | ||
| US62/266,233 | 2015-12-11 | ||
| PCT/EP2016/079737 WO2017097699A1 (en) | 2015-12-11 | 2016-12-05 | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021063261A Division JP7513562B2 (ja) | 2015-12-11 | 2021-04-02 | 様々ながんに対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019506838A JP2019506838A (ja) | 2019-03-14 |
| JP2019506838A5 true JP2019506838A5 (enExample) | 2020-01-30 |
| JP7229516B2 JP7229516B2 (ja) | 2023-02-28 |
Family
ID=55274600
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519334A Active JP7229516B2 (ja) | 2015-12-11 | 2016-12-05 | 様々ながんに対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ |
| JP2021063261A Active JP7513562B2 (ja) | 2015-12-11 | 2021-04-02 | 様々ながんに対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021063261A Active JP7513562B2 (ja) | 2015-12-11 | 2021-04-02 | 様々ながんに対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ |
Country Status (18)
| Country | Link |
|---|---|
| US (15) | US10967053B2 (enExample) |
| EP (1) | EP3325498A1 (enExample) |
| JP (2) | JP7229516B2 (enExample) |
| KR (1) | KR20180085725A (enExample) |
| CN (1) | CN108602854A (enExample) |
| AU (1) | AU2016368433B2 (enExample) |
| BR (1) | BR112018008806A2 (enExample) |
| CA (1) | CA3007382A1 (enExample) |
| CR (1) | CR20180245A (enExample) |
| EA (1) | EA201891116A1 (enExample) |
| GB (1) | GB201521894D0 (enExample) |
| MA (3) | MA42494A (enExample) |
| MX (1) | MX2018005374A (enExample) |
| PE (1) | PE20181316A1 (enExample) |
| PH (1) | PH12018500551A1 (enExample) |
| SG (2) | SG10202101368WA (enExample) |
| TW (1) | TWI689516B (enExample) |
| WO (1) | WO2017097699A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10988543B2 (en) | 2015-11-11 | 2021-04-27 | Opi Vi—Ip Holdco Llc | Humanized anti-tumor necrosis factor alpha receptor 2 (anti-TNFR2) antibodies and methods of use thereof to elicit an immune response against a tumor |
| GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
| GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520595D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| HK1255541A1 (zh) | 2015-12-11 | 2019-08-23 | Immatics Biotechnologies Gmbh | 用於多种癌症免疫治疗的新型肽和肽组合物 |
| CN109310739A (zh) * | 2016-03-31 | 2019-02-05 | 内恩疗法公司 | 新抗原及其使用方法 |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| KR102379955B1 (ko) | 2016-12-08 | 2022-03-29 | 이매틱스 바이오테크놀로지스 게엠베하 | 짝짓기가 향상된 t 세포 수용체 |
| CR20190509A (es) | 2017-04-10 | 2020-01-08 | Immatics Biotechnologies Gmbh | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cáncer |
| EA201992416A1 (ru) | 2017-04-10 | 2020-02-25 | Имматикс Байотекнолоджиз Гмбх | Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака |
| GB201709866D0 (en) * | 2017-06-20 | 2017-08-02 | Immunocore Ltd | T cell receptors |
| DE102017114737A1 (de) | 2017-06-30 | 2019-01-03 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| US20190016802A1 (en) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Dual specificity polypeptide molecule |
| CA3080835A1 (en) * | 2017-10-31 | 2019-05-09 | Pantarhei Bioscience B.V. | Immunotherapeutic methods for treating and/or preventing lung cancer |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| US10692605B2 (en) | 2018-01-08 | 2020-06-23 | International Business Machines Corporation | Library screening for cancer probability |
| US11464800B2 (en) | 2018-02-09 | 2022-10-11 | Immatics US, Inc. | Methods for manufacturing T cells |
| DE102018107224A1 (de) * | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| TW202016131A (zh) | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | 用於抗癌免疫治療的肽 |
| TW202019955A (zh) * | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
| US20210317165A1 (en) * | 2018-09-03 | 2021-10-14 | Laboratoire Hra-Pharma | Zp3 fragments in immunotherapy of ovarian cancer |
| MA53599A (fr) * | 2018-09-14 | 2021-07-21 | Immatics Biotechnologies Gmbh | Procédé de criblage par affinité peptide-cmh à haut débit destiné à des ligands de tcr |
| TW202024121A (zh) * | 2018-09-18 | 2020-07-01 | 德商英麥提克生物技術股份有限公司 | A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法 |
| CA3112427A1 (en) | 2018-10-19 | 2020-04-23 | The Francis Crick Institute Limited | Novel cancer antigens and methods |
| JP7216995B2 (ja) * | 2018-12-05 | 2023-02-02 | 学校法人関西医科大学 | 胸腺癌バイオマーカー及び胸腺腫瘍の予後予測マーカー |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| PH12021552979A1 (en) | 2019-05-27 | 2023-10-09 | Immatics Us Inc | Viral vectors and their use in adoptive cellular therapy |
| CN114303060A (zh) | 2019-06-06 | 2022-04-08 | 伊玛提克斯生物技术有限公司 | 使用序列相似肽进行反向选择分选 |
| CN114174323B (zh) * | 2019-07-05 | 2025-01-07 | 弗朗西斯·克里克研究所有限公司 | 新的癌抗原和方法 |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| IL295891A (en) | 2020-02-24 | 2022-10-01 | Immatics Us Inc | Methods for propagating t cells for the treatment of cancer and related malignancies |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| CN113416253B (zh) * | 2021-05-24 | 2022-12-13 | 复旦大学 | 分离的抗原itpripl1结合蛋白及其用途 |
| WO2022147029A2 (en) | 2020-12-31 | 2022-07-07 | Immatics US, Inc. | Cd8 polypeptides, compositions, and methods of using thereof |
| IL308258A (en) | 2021-05-05 | 2024-01-01 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
| US20250231185A1 (en) * | 2021-05-13 | 2025-07-17 | La Jolla Institute For Immunology | Coronavirus T Cell Epitopes, Megapools and Uses Thereof |
| JP2024534825A (ja) | 2021-08-24 | 2024-09-26 | イマティクス ユーエス，アイエヌシー． | 条件付きリガンド交換により産生されたペプチドｍｈｃ複合体を使用する免疫細胞の選択 |
| TW202332765A (zh) | 2021-09-20 | 2023-08-16 | 美商英麥提克斯股份有限公司 | 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡 |
| CN118541392A (zh) | 2021-09-28 | 2024-08-23 | 准星生物医药有限公司 | 多种形式的分子复合物 |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| US20250161421A1 (en) | 2022-02-03 | 2025-05-22 | CeCaVa GmbH & Co. KG | Co-vaccination with cd4 and cd8 antigens |
| CN114736298B (zh) * | 2022-04-08 | 2023-12-12 | 陕西脉元生物科技有限公司 | 用于检测自身免疫系统疾病的抗Shroom2自身抗体及其产品和应用 |
| AU2023262596A1 (en) | 2022-04-28 | 2024-12-05 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| EP4514821A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| CN115785204B (zh) * | 2022-06-10 | 2024-02-13 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标08及其用途 |
| CN116814642B (zh) * | 2023-07-17 | 2024-09-17 | 南通大学 | 一种预测肝癌患者预后的生物标志物及其应用 |
| WO2025040598A2 (en) * | 2023-08-18 | 2025-02-27 | Immatics Biotechnologies Gmbh | Peptides displayed by mhc for use in immunotherapy against different types of cancer |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1118860A1 (en) * | 2000-01-21 | 2001-07-25 | Rijksuniversiteit te Leiden | Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes |
| AUPQ776100A0 (en) * | 2000-05-26 | 2000-06-15 | Australian National University, The | Synthetic molecules and uses therefor |
| US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US20030118585A1 (en) | 2001-10-17 | 2003-06-26 | Agy Therapeutics | Use of protein biomolecular targets in the treatment and visualization of brain tumors |
| EP2143438B1 (en) | 2001-09-18 | 2011-07-13 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumors |
| EP1576139A4 (en) | 2002-11-26 | 2007-06-20 | Cold Spring Harbor Lab | INTERACTIVE PROTEINS AND ASSOCIATED METHODS OF DEP-1 RECEPTOR PROTEIN-TYROSINE PHOSPHATASE |
| CN1253469C (zh) * | 2003-11-28 | 2006-04-26 | 北京大学 | 人的肿瘤－睾丸抗原hca587的抗原决定簇多肽及其用途 |
| US7399469B2 (en) | 2004-03-26 | 2008-07-15 | Pdl Biopharma, Inc. | Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
| US8168602B2 (en) | 2005-02-17 | 2012-05-01 | Dana-Farber Cancer Institute, Inc. | Compositions, kits and methods for identification, assessment, prevention and therapy of cancer |
| US7608413B1 (en) | 2005-03-25 | 2009-10-27 | Celera Corporation | Kidney disease targets and uses thereof |
| US7842467B1 (en) | 2005-05-12 | 2010-11-30 | Celera Corporation | Breast disease targets and uses thereof |
| US7504225B2 (en) * | 2005-05-12 | 2009-03-17 | Applied Genomics, Inc. | Reagents and methods for use in cancer diagnosis, classification and therapy |
| EP1760089B1 (en) * | 2005-09-05 | 2009-08-19 | Immatics Biotechnologies GmbH | Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine |
| US7964365B2 (en) | 2005-11-08 | 2011-06-21 | The United States of Americam as represented by the Secretary, Department of Health and Human Services | Methods for diagnosing and monitoring the progression of cancer |
| US7358231B1 (en) | 2005-12-01 | 2008-04-15 | Applera Corporation | Pancreatic cancer secreted targets and uses thereof |
| WO2008021290A2 (en) | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| US7910565B2 (en) * | 2006-09-01 | 2011-03-22 | Wisconsin Alumni Research Foundation | Prostate cancer vaccine |
| CN101066991A (zh) * | 2007-06-13 | 2007-11-07 | 北京大学 | 人肿瘤－睾丸抗原hca587的抗原决定簇多肽及其应用 |
| KR101351195B1 (ko) * | 2007-07-27 | 2014-01-14 | 이매틱스 바이오테크놀로지스 게엠베하 | 면역 치료를 위한 새로운 면역원성 에피톱 |
| US7960134B1 (en) | 2007-08-01 | 2011-06-14 | Arqule, Inc. | Kinase inhibition models and their uses |
| US7892770B2 (en) | 2007-08-24 | 2011-02-22 | Van Andel Research Institute | Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods |
| WO2009036246A2 (en) * | 2007-09-14 | 2009-03-19 | Immunotope, Inc. | Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer |
| GB0721686D0 (en) * | 2007-11-05 | 2007-12-12 | Medinnova As | Polypeptides |
| WO2009142738A2 (en) | 2008-05-21 | 2009-11-26 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| CA2840472A1 (en) | 2011-06-22 | 2012-12-27 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of bladder cancer |
| NL2007536C2 (en) * | 2011-10-05 | 2013-04-08 | Academisch Ziekenhuis Leiden Lumc | Adjuvant compound. |
| WO2014127296A1 (en) * | 2013-02-14 | 2014-08-21 | Immunocellular Therapeutics, Ltd | Cancer vaccines and vaccination methods |
| TWI714869B (zh) | 2013-08-05 | 2021-01-01 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物 |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201408255D0 (en) * | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
| GB201520595D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| EP3383418B1 (en) * | 2015-12-04 | 2021-10-20 | Board of Regents, The University of Texas System | Slc45a2 peptides for immunotherapy |
-
2015
- 2015-12-11 GB GBGB1521894.4A patent/GB201521894D0/en not_active Ceased
-
2016
- 2016-12-05 MA MA042494A patent/MA42494A/fr unknown
- 2016-12-05 WO PCT/EP2016/079737 patent/WO2017097699A1/en not_active Ceased
- 2016-12-05 MA MA43490A patent/MA43490A1/fr unknown
- 2016-12-05 KR KR1020187014106A patent/KR20180085725A/ko not_active Ceased
- 2016-12-05 PE PE2018000553A patent/PE20181316A1/es unknown
- 2016-12-05 MA MA42073A patent/MA42073A1/fr unknown
- 2016-12-05 CA CA3007382A patent/CA3007382A1/en active Pending
- 2016-12-05 AU AU2016368433A patent/AU2016368433B2/en not_active Ceased
- 2016-12-05 SG SG10202101368WA patent/SG10202101368WA/en unknown
- 2016-12-05 CR CR20180245A patent/CR20180245A/es unknown
- 2016-12-05 MX MX2018005374A patent/MX2018005374A/es unknown
- 2016-12-05 BR BR112018008806-4A patent/BR112018008806A2/pt not_active IP Right Cessation
- 2016-12-05 CN CN201680072386.4A patent/CN108602854A/zh active Pending
- 2016-12-05 EA EA201891116A patent/EA201891116A1/ru unknown
- 2016-12-05 JP JP2018519334A patent/JP7229516B2/ja active Active
- 2016-12-05 SG SG11201801756WA patent/SG11201801756WA/en unknown
- 2016-12-05 EP EP16805839.4A patent/EP3325498A1/en active Pending
- 2016-12-09 US US15/375,017 patent/US10967053B2/en not_active Expired - Fee Related
- 2016-12-09 US US15/374,975 patent/US10058598B2/en active Active
- 2016-12-09 US US15/375,058 patent/US10117917B2/en active Active
- 2016-12-09 US US15/375,047 patent/US10098938B2/en active Active
- 2016-12-09 US US15/375,030 patent/US10098937B2/en active Active
- 2016-12-09 US US15/375,037 patent/US10143731B2/en active Active
- 2016-12-09 US US15/374,993 patent/US10004792B2/en active Active
- 2016-12-09 TW TW105140777A patent/TWI689516B/zh not_active IP Right Cessation
- 2016-12-09 US US15/374,452 patent/US10143730B2/en active Active
- 2016-12-09 US US15/374,912 patent/US20170189507A1/en not_active Abandoned
- 2016-12-09 US US15/374,415 patent/US20170189504A1/en not_active Abandoned
- 2016-12-09 US US15/374,882 patent/US10179165B2/en active Active
- 2016-12-09 US US15/375,051 patent/US10279022B2/en active Active
-
2018
- 2018-03-14 PH PH12018500551A patent/PH12018500551A1/en unknown
- 2018-08-21 US US16/106,951 patent/US10314896B2/en active Active
- 2018-08-21 US US16/106,962 patent/US10314897B2/en active Active
- 2018-08-29 US US16/116,323 patent/US10342859B2/en active Active
-
2021
- 2021-04-02 JP JP2021063261A patent/JP7513562B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506838A5 (enExample) | ||
| JP2019502360A5 (enExample) | ||
| JP2019510465A5 (enExample) | ||
| JP2018529320A5 (enExample) | ||
| JP2018510628A5 (enExample) | ||
| JP2019511214A5 (enExample) | ||
| JP2018509135A5 (enExample) | ||
| JP2018519243A5 (enExample) | ||
| JP2021168652A5 (enExample) | ||
| JP2018536383A5 (enExample) | ||
| JP2018511321A5 (enExample) | ||
| JP2018518937A5 (enExample) | ||
| JP2018520653A5 (enExample) | ||
| JP2024099580A5 (enExample) | ||
| JP2024041841A5 (enExample) | ||
| JP2017525336A5 (enExample) | ||
| RU2017137142A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| JP2018521641A5 (enExample) | ||
| CN107735492B (zh) | 使用活化t细胞治疗癌的方法 | |
| JP2020530759A5 (enExample) | ||
| JP2017502076A5 (enExample) | ||
| JP2018518956A5 (enExample) | ||
| JP2017524337A5 (enExample) | ||
| JP2020516681A5 (enExample) | ||
| FI3273986T3 (fi) | Uusia peptidejä ja peptidien yhdistelmiä käytettäväksi immunoterapiassa eri syöpiä vastaan |